ICD-10 code L83: Acanthosis nigricans diagnosis and billing guide

Key Takeaways

ICD-10 code L83 is the billable diagnosis code for acanthosis nigricans, a skin condition producing velvety, hyperpigmented patches in body folds such as the axillae and neck.

L83 is valid for reimbursement under CMS ICD-10-CM guidelines and maps exactly to ICD-9-CM code 701.2 (Acquired acanthosis nigricans).

Accurate documentation must specify the clinical presentation, anatomical site, and the underlying etiology (endocrine, malignancy-related, drug-induced, or inherited) to support medical necessity.

Pabau’s claims management software and digital intake forms help dermatology and endocrinology practices document L83 encounters correctly and reduce claim denials.

ICD-10 code L83 is the billable diagnosis code for acanthosis nigricans, a velvety, hyperpigmented skin change appearing in body folds such as the axillae and neck. It covers a single condition with four distinct etiologies — endocrine, paraneoplastic, drug-induced, and inherited — each requiring different supporting documentation to satisfy payer requirements.

This reference covers the L83 code definition, classification hierarchy, applicable conditions, ICD-9 crosswalk, documentation requirements, coding rules, and practical billing guidance for 2026.

ICD-10 code L83: definition and classification

ICD-10 code L83 designates acanthosis nigricans, described in the CMS tabular list as circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. The condition occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as an inherited disorder, according to the CMS ICD-10-CM official code descriptions.

L83 is classified within:

• Chapter 12: Diseases of the skin and subcutaneous tissue (L00-L99)
• Block L80-L99: Other disorders of the skin and subcutaneous tissue
• Code L83: Acanthosis nigricans (billable, specific)

The code has no subcategories and no child codes. It is a standalone billable code at its level in the tabular hierarchy. Coders should not attempt to add a fifth or sixth character; L83 is complete as listed.

Applicable to: confluent and reticulated papillomatosis

The ICD-10-CM tabular list includes an “Applicable To” note under L83 for confluent and reticulated papillomatosis. This means clinicians documenting confluent and reticulated papillomatosis (also known as Gougerot-Carteaud syndrome) should also use L83 as the appropriate diagnosis code. The two conditions share overlapping morphological features (papillomatous, pigmented skin changes) and are grouped under the same classification entry.

ICD-9-CM crosswalk: mapping to code 701.2

Practices transitioning legacy records or reconciling pre-2015 claims will encounter ICD-9-CM code 701.2. According to the CDC/NCHS ICD-10-CM lookup tool, L83 maps to ICD-9-CM 701.2 as an exact (non-approximate) crosswalk via CMS General Equivalence Mappings (GEMs).

The crosswalk is exact in both directions. A claim previously filed with 701.2 maps cleanly to L83 without ambiguity, which simplifies audits and retrospective chart reviews for skin clinic software users managing historical patient data.

Associated conditions and etiologies

Acanthosis nigricans is not a single-cause condition. The etiology informs both documentation and, in many cases, which additional codes must be assigned alongside L83. Coders and clinicians in dermatology and metabolic health practices should be familiar with all four recognized categories.

Insulin resistance and endocrine disorders

The most common etiology. Acanthosis nigricans frequently presents as a cutaneous marker of insulin resistance and is strongly associated with type 2 diabetes mellitus, obesity, and metabolic syndrome. When the underlying endocrine condition is the reason for the encounter, code the endocrine condition as the principal diagnosis and L83 as a secondary code. Payer policies vary on whether L83 may be the primary code when the skin presentation is the stated reason for the visit.

Paraneoplastic acanthosis nigricans and malignancy

Acanthosis nigricans can be a paraneoplastic phenomenon, appearing in association with internal malignancy, most commonly gastrointestinal adenocarcinoma. When malignancy is documented as the underlying cause or is a known concurrent condition, code the malignancy separately, in accordance with CMS ICD-10-CM Official Guidelines for Coding and Reporting.

This distinction carries medical necessity implications for payers. Clinicians should note whether the acanthosis nigricans presentation prompted an initial oncologic workup, as this affects coding sequence and clinical documentation requirements.

Drug-induced acanthosis nigricans

Certain medications have been implicated in drug-induced acanthosis nigricans. When drug causation is documented, an adverse effect code from the ICD-10-CM Table of Drugs and Chemicals should be assigned in addition to L83. The sequencing follows standard adverse effect coding rules: the manifestation (L83) first, then the adverse effect code. The prescribing clinician’s documentation must clearly support the causal relationship.

Inherited and familial acanthosis nigricans

A small subset of cases is hereditary, with an autosomal dominant inheritance pattern. In inherited presentations, L83 is typically assigned as the primary diagnosis without an additional etiology code. Documentation should specify the hereditary nature of the condition when this is clinically established, which supports medical necessity for dermatological management and follow-up billing. Well-structured patient record documentation capturing family history entries at intake strengthens this position.

Documentation requirements

Accurate documentation is the single biggest variable in whether an L83 claim pays on first submission. The digital intake forms and structured encounter templates that a practice uses directly influence documentation completeness. Requirements span clinical description, anatomical site, etiology, and supporting workup.

• Clinical presentation: Document the texture (velvety, verrucous, papillomatous), color (brown, gray, or black hyperpigmentation), and distribution of lesions. Objective description supports the L83 diagnosis.
• Anatomical location: Specify the affected body fold or skin area: axillae, posterior neck, groin, antecubital fossae, or other sites. L83 does not have site-specific subcodes, but location documentation supports specificity within the medical record.
• Etiology or associated condition: Note any concurrent diagnoses (diabetes mellitus, obesity, malignancy, medication exposure) to support sequencing decisions and medical necessity.
• Duration and course: Indicate whether the condition is new, chronic, or progressive. Changes in severity can justify additional encounters and follow-up coding.
• Workup ordered or completed: Document any laboratory investigations (fasting glucose, HbA1c, insulin levels) or imaging/referrals triggered by the presentation, particularly when malignancy is in the differential.

A note that reads only “acanthosis nigricans, axillae” meets the minimum code-assignment threshold but often fails payer scrutiny for medical necessity. Attach the clinical context, associated diagnoses, and the plan of care to every L83 encounter. HIPAA-compliant clinical documentation standards require that the record support any code submitted on the claim.

Document L83 encounters accurately, every time

Pabau's structured intake forms and claims management tools help dermatology and skin care practice teams capture the etiology, site, and clinical context needed to bill L83 without denials.

Book a demo

Billable status and coding rules

ICD-10 code L83 is a billable and specific code, valid for use on claims submitted for reimbursement in fiscal year 2026. It is confirmed as active in the CDC/NCHS ICD-10-CM code set and recognized by CMS for Medicare and Medicaid reimbursement purposes.

Primary vs. secondary diagnosis sequencing

L83 may be used as either the primary diagnosis or a secondary diagnosis, depending on the clinical context of the encounter.

• L83 as primary: When acanthosis nigricans is the stated reason for the visit and no underlying cause is the focus of care (common in initial dermatology consultations or when etiology is idiopathic/inherited).
• L83 as secondary: When the encounter is primarily for an underlying condition such as type 2 diabetes mellitus, obesity, or a malignancy, and L83 is an additional finding addressed during the encounter.

CMS ICD-10-CM Official Guidelines specify that when the condition is an integral manifestation of another disease, sequencing follows the underlying condition first. Practices using claims management software should configure encounter templates that prompt coders to record both the primary and secondary diagnosis codes, and flag encounters where L83 appears without a supporting etiology code for review before submission.

Excludes and related code notes

The ICD-10-CM tabular list does not apply an Excludes1 or Excludes2 note directly to L83. Coders should still be attentive to several nearby codes in the L80-L99 block that could create confusion:

• L81.x (Other disorders of pigmentation): Covers melasma, lentigo, and other pigmentary changes. Do not substitute for L83 when the clinical diagnosis is specifically acanthosis nigricans.
• L82.x (Seborrheic keratosis): Sometimes confused visually with acanthosis nigricans in less experienced documentation. The clinical distinction matters for code accuracy.
• L85.x (Other epidermal thickening): Used for ichthyosis and keratoderma presentations, not acanthosis nigricans.

Reviewing related pigmentation codes such as L81.4 can help coders understand how comorbidity sequencing principles apply consistently to skin disorder codes like L83.

CPT codes commonly billed with acanthosis nigricans

L83 is a diagnosis code, not a procedure code. It must be paired with the appropriate CPT or HCPCS procedure code for each claim line. The procedures billed will depend on the clinical specialty and the services rendered during the encounter. Dermatology and endocrinology practices should reference the AAPC Codify ICD-10-CM lookup for crosswalk support, and consulting related codes such as diabetes-related ICD-10 coding can help coders apply consistent sequencing logic across specialties.

Note that laboratory services ordered as part of an L83 evaluation are typically billed separately by the performing laboratory. Practice billing teams should not include lab panel CPT codes on the same claim as the office visit unless the practice meets the criteria for performing and billing ancillary services directly. Automated billing workflows that separate encounter-level charges from ancillary orders reduce this common billing error. Using compliance management tools within your EHR can flag mixed-claim patterns before submission.

Conclusion

Most L83 denials are preventable. The code is billable and unambiguous, but the documentation around it is where practices lose revenue: missing etiology, absent anatomical detail, or incorrect sequencing when a comorbidity is present.

Pabau’s structured encounter templates and claims management software help dermatology and skin care practice teams capture every element needed to submit clean L83 claims on first pass. To see how Pabau handles diagnostic code documentation workflows, book a demo.

Expert picks

Continue your research

Running a dermatology or skin care practice and need smarter software? Dermatology EMR software covers the features most relevant to skin-focused practices managing diagnostic codes and clinical workflows.

Want to reduce administrative burden on your clinical team? Digital intake forms capture structured patient data at intake, capturing complete documentation before the encounter begins.

Looking for related dermatology coding references? ICD-10 coding for keratoderma (L86) help coders apply consistent sequencing principles across specialties.

Frequently Asked Questions